Drug details
Vyxeos (daunorubicin and cytarabine for injection)
type of Antineoplastics, Antimetabolite, Antineoplastics, Anthracycline
Vyxeos (daunorubicin and cytarabine) liposome for injection, for intravenous use, is a liposomal combination of an anthracycline topoisomerase inhibitor and a nucleoside metabolic inhibitor, indicated for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).
This drug may have the following side effects:
- hives,
- difficulty breathing,
- swelling of your face, lips, tongue, or throat,
- fever,
- easy bruising,
- shortness of breath,
- chills,
- chest pain,
- dizziness,
- dry mouth,
- swelling,
- weakness,
- severe stomach pain,
- rapid weight gain,
- sudden numbness or weakness (especially on one side of the body),
- problems with vision or balance,
- coughing up blood,
- vomit that looks like coffee grounds,
- skin sores,
- swollen gums,
- cold or flu symptoms,
- fainting
- cough with mucus,
- unusual bleeding (nose, mouth, vagina, rectum),
- any bleeding that will not stop,
- trouble swallowing or talking,
- sudden severe headache,
- black or bloody stools,
- pain, burning, irritation, or skin changes where the injection was given,
- severe or ongoing diarrhea,
- wheezing, and
- sores or white patches in or around your mouth,
- bad breath,
- altered sense of taste,
- fast, slow, or uneven heart rate,
The following drugs are related to Vyxeos, either as a replacement or used together:
- Anthim (obiltoxaximab intravenous infusion)
- Beleodaq (belinostat for injection for intravenous use)
- Bexxar (tositumomab and iodine 1131 tositumomab)
- Daurismo (glasdegib tablets)
- Decadron (dexamethasone)
- Idhifa (enasidenib tablets)
- Xospata (gilteritinib tablets)
- Zevalin (ibritumomab tiuxetan)